Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2014

01-03-2014 | Mini Review

Management of hyperthyroidism in pregnancy

Author: John H. Lazarus

Published in: Endocrine | Issue 2/2014

Login to get access

Excerpt

The commonest cause of hyperthyroidism in pregnancy is Graves’ disease due to stimulation of the thyroid by thyrotrophin receptor-stimulating antibodies (TRAb), but other causes such as toxic multinodular goiter, toxic adenoma, and subacute thyroiditis may occur. Rarer causes include struma ovarii, hyperemesis gravidarum, and hydatidiform mole [1]. …
Literature
1.
H. Marx, P. Amin, J.H. Lazarus, Pregnancy plus: hyperthyroidism and pregnancy. Br. Med. J. 336, 663–667 (2008)CrossRef
2.
W.M. Tunbridge, D.C. Evered, R. Hall, D. Appleton, M. Brewis, F. Clark, J.G. Evans, E. Young, T. Bird, P.A. Smith, The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf). 7, 481–493 (1977)PubMedCrossRef
3.
F. Aghini-Lombardi, L. Antonangeli, E. Martino, P. Vitti, D. Maccherini, F. Leoli, T. Rago, L. Grasso, R. Valeriano, A. Balestrieri, A. Pinchera, The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J. Clin. Endocrinol. Metab. 84, 561–566 (1999)PubMed
4.
G.E. Krassas, K. Poppe, D. Glinoer, Thyroid function and human reproductive health. Endocr. Rev. 31, 702–755 (2010)PubMedCrossRef
5.
C.P. Yeo, D.H. Khoo, P.H. Eng, H.K. Tan, S.L. Yo, E. Jacob, Prevalence of gestational thyrotoxicosis in Asian women evaluated in the 8th to 14th weeks of pregnancy: correlations with total and free beta human chorionic gonadotrophin. Clin Endocrinol (Oxf) 55, 391–398 (2001)CrossRef
6.
R. Moreno-Reyes, D. Glinoer, H. Van Oyen, S. Vandevijvere, High prevalence of thyroid disorders in pregnant women in a mildly iodine-deficient country: a population-based study. J. Clin. Endocrinol. Metab. 98, 3694–3701 (2013)PubMedCrossRef
7.
B. Casey, Maternal hypothyroidism and hyperthyroidism, in Management of high-risk pregnancy, ed. by J.T. Queenan, C.Y. Spong, C.J. Lockwood (Wiley, New Jersey, 2007), p. 187
8.
9.
J.H. Lazarus, O. Soldin, C. Evans, Assessing thyroid function in pregnancy, in Thyroid function testing, ed. by G. Brent (Springer, New York, 2010), pp. 209–233CrossRef
10.
J.E. Midgley, R. Hoermann, Measurement of total rather than free thyroxine in pregnancy: the diagnostic implications. Thyroid 23, 259–261 (2013)PubMedCrossRef
11.
R.M. Gilbert, N.C. Hadlow, J.P. Walsh, S.J. Fletcher, S.J. Brown, B.G. Stuckey, E.M. Lim, Assessment of thyroid function during pregnancy: first-trimester (weeks 9–13) reference intervals derived from Western Australian women. Med. J. Aust. 189, 250–253 (2008)PubMed
12.
J.P. Bestwick, R. John, A. Maina, V. Guaraldo, M. Joomun, N.J. Wald, J.H. Lazarus, Use of multiple of the median (MoM) values in the evaluation of thyroid hormones in Pregnancy. Clin. Chem. (2013, in press)
13.
R.A. Aijan, A.P. Weetman, Thyroid autoantibody measurements, in Thyroid function testing, ed. by G. Brent (Springer, New York, 2010), pp. 109–124CrossRef
14.
J.H. Mestman, Hyperthyroidism in pregnancy. Endoc. Metab. Clins. N. Am. 27, 127–149 (1998)CrossRef
15.
L.K. Millar, D.A. Wing, A.S. Leung, P.P. Koonings, M.N. Montoro, J.H. Mestman, Low birth weight and pre-eclampsia in pregnancies complicated by hyperthyroidism. Obs Gyn 84, 946–949 (1994)
16.
U.R. Maziukiewicz, G.N. Burrow, Hyperthyroidism in pregnancy, diagnosis and treatment. Thyroid 9, 647–652 (1999)CrossRef
17.
J.I. Hamburger, Diagnosis and management of Graves’ disease in pregnancy. Thyroid 2, 219–224 (1992)PubMedCrossRef
18.
A.W.C. Kung, B.M. Jones, A change from stimulatory to blocking antibody activity in Graves’ disease during pregnancy. J Clin Endoc Metab 83, 514–518 (1998)
19.
M. Zakarija, R. De Forteza, J.M. McKenzie, L. Ghandur-Mnaymneh, Characteristics and clinical correlates of a novel thyroid-stimulating autoantibody. Autoimmunity 19, 31–37 (1994)PubMedCrossRef
20.
Y. Ueta, H. Fukui, H. Murakami, Y. Yamanoughi, R. Yamamoto, Development of primary hypothyroidism with the appearance of blocking-type antibody to thyrotropin receptor in Graves’ disease in late pregnancy. Thyroid 9, 179–182 (1999)PubMedCrossRef
21.
G. Radetti, L. Persani, W. Moroder, D. Cortelazzi, L. Gentili, P. Beck-Peccoz, Transplacental passage of anti-thyroid auto-antibodies in a pregnant woman with auto-immune thyroid disease. Prenat. Diagn. 19, 468–471 (1999)PubMedCrossRef
22.
H. John Lazarus, Pre-conception counselling in Graves’ disease. Eur Thyroid J 1, 24–29 (2012)CrossRef
23.
J.H. Lazarus, J.H. Mestman, Thyroid disorders during pregnancy and postpartum, in Werner and Ingbar’s. The thyroid, 10th edn., ed. by L.E. Braverman, D.S. Cooper (Lippincott Williams and Wilkins, Philadelphia, 2013), pp. 815–835
24.
A.B. Emiliano, L. Governale, M. Parks, D.S. Cooper, Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J. Clin. Endocrinol. Metab. 95, 2227–2233 (2010)PubMedCrossRef
25.
E.B. Astwood, The use of antithyroid drugs in pregnancy. J. Clin. Endocrinol. 11, 1045–1056 (1951)CrossRef
26.
A. Yoshihara, J. Noh, T. Yamaguchi, H. Ohye, S. Sato, K. Sekiya, Y. Kosuga, M. Suzuki, M. Matsumoto, Y. Kunii, N. Watanabe, K. Mukasa, K. Ito, K. Ito, Treatment of Graves’ disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J. Clin. Endocrinol. Metab. 97, 2396–2403 (2012)PubMedCrossRef
27.
A. Stagnaro-Green, M. Abalovich, E. Alexander, F. Azizi, J. Mestman, R. Negro, A. Nixon, E.N. Pearce, O.P. Soldin, S. Sullivan, W. Wiersinga, American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum, Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 21, 1081–1125 (2011)PubMedCrossRef
28.
R.S. Bahn, H.B. Burch, D.S. Cooper, J.R. Garber, M.C. Greenlee, I. Klein, P. Laurberg, I.R. McDougall, V.M. Montori, S.A. Rivkees, D.S. Ross, J.A. Sosa, M.N. Stan, American Thyroid Association; American Association of Clinical Endocrinologists, Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21, 593–646 (2011)CrossRef
29.
L. De Groot, M. Abalovich, E.K. Alexander, N. Amino, L. Barbour, R.H. Cobin, C.J. Eastman, J.H. Lazarus, D. Luton, S.J. Mandel, J. Mestman, J. Rovet, Sullivan S Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 97, 2543–2565 (2012)PubMedCrossRef
30.
N. Momotani, J. Noh, H. Oyanagi, N. Ishikawa, K. Ito, Antithyroid drug therapy for Graves’ disease during pregnancy. Optimal regimen for fetal thyroid status. N. Engl. J. Med. 315, 24–28 (1986)PubMedCrossRef
31.
S.J. Mandel, D.S. Cooper, The use of antithyroid drugs in pregnancy and lactation. J. Clin. Endocrinol. Metab. 86, 2354–2359 (2001)PubMedCrossRef
32.
Y. Nakagawa, K. Mori, S. Hoshikawa, M. Yamamoto, S. Ito, K. Yoshida, Postpartum recurrence of Graves’ hyperthyroidism can be prevented by the continuation of antithyroid drugs during pregnancy. Clin Endocrinol (Oxf). 57, 467–471 (2002)PubMedCrossRef
33.
M. Rotondi, C. Cappelli, B. Pirali, I. Pirola, F. Magri, R. Fonte, M. Castellano, E.A. Rosei, L. Chiovato, The effect of pregnancy on subsequent relapse from Graves’ disease after a successful course of antithyroid drug therapy. J. Clin. Endocrinol. Metab. 93, 3985–3988 (2008)PubMedCrossRef
34.
N. Momotani, T. Hisaoka, J. Noh, N. Ishikawa, K. Ito, Effects of iodine on thyroid status of fetus versus mother in treatment of Graves’ disease complicated by pregnancy. J. Clin. Endocrinol. Metab. 75, 738–744 (1992)PubMed
35.
P. Laurberg, C. Bournaud, J. Karmisholt, J. Orgiazzi, Management of Graves’ hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. Eur. J. Endocrinol. 160, 1–8 (2009)PubMedCrossRef
36.
J. Anselmo, D. Cao, T. Karrison, R.E. Weiss, S. Refetoff, Fetal loss associated with excess thyroid hormone exposure. JAMA 292, 691–695 (2004)PubMedCrossRef
37.
J.J. Giles, J.G. Bannigan, Teratogenic and developmental effects of lithium. Curr. Pharm. Des. 12(12), 1531–1541 (2006)PubMedCrossRef
38.
K. Meidahl Petersen, E. Jimenez-Solem, J.T. Andersen, M. Petersen, K. Brødbæk, L. Køber, C. Torp-Pedersen, H.E. Poulsen, β-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open. doi:10.1136/bmjopen-2012-001185 (2012)
39.
P. Laurberg, B. Nygaard, D. Glinoer, M. Grussendorf, J. Orgiazzi, Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European Thyroid Association. Eur. J. Endocrinol. 139, 584–586 (1998)PubMedCrossRef
40.
D. Luton, I. Le Gac, E. Vuillard, M. Castanet, J. Guibourdenche, M. Noel, M.E. Toubert, J. Léger, C. Boissinot, M.H. Schlageter, C. Garel, B. Tébeka, J.F. Oury, P. Czernichow, M. Polak, Management of Graves’ disease during pregnancy: the key role of fetal thyroid gland monitoring. J Clin Endocrinol Metab 90, 6093–6098 (2005)PubMedCrossRef
41.
P. Papendieck, A. Chiesa, L. Prieto, L. Gruñeiro-Papendieck, Thyroid disorders of neonates born to mothers with Graves’ disease. J. Pediatr. Endocrinol. Metab. 22, 547–553 (2009)PubMedCrossRef
42.
K. Johansen, A.N. Andersen, J.P. Kampmann, J.M. Mølholm Hansen, H.B. Mortensen, Excretion of methimazole in human milk. Eur. J. Clin. Pharmacol. 23, 339–341 (1982)PubMedCrossRef
43.
F. Azizi, M. Khoshniat, M. Bahrainian, M. Hedayati, Thyroid function and intellectual development of infants nursed by mothers taking methimazole. J. Clin. Endocrinol. Metab. 85, 3233–3238 (2000)PubMedCrossRef
Metadata
Title
Management of hyperthyroidism in pregnancy
Author
John H. Lazarus
Publication date
01-03-2014
Publisher
Springer US
Published in
Endocrine / Issue 2/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-013-0086-9

Other articles of this Issue 2/2014

Endocrine 2/2014 Go to the issue

Original Article

Ischemic stroke functional outcomes are independently associated with C-reactive protein concentrations and cognitive outcomes with triiodothyronine concentrations: a pilot study

Original Article

New technologies aiding dietary programmes for weight control: the oral glucose spray

Original Article

Endurance training enhances skeletal muscle interleukin-15 in human male subjects

Original Article

MicroRNA-17-92 cluster regulates osteoblast proliferation and differentiation

Endocrine Imaging

Occult pyogenic liver abscess in an adolescent with type 2 diabetes

Original article

Comparison of high-sensitivity C-reactive protein and fetuin-A levels before and after treatment for subjects with subclinical hyperthyroidism
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits